Denali Therapeutics (DNLI)
NASDAQ:DNLI
Holding DNLI?
Track your performance easily

Denali Therapeutics (DNLI) Ownership - Who Owns Denali Therapeutics?

623 Followers

Denali Therapeutics (DNLI) Ownership Overview

9.09%30.89%9.78%14.57%35.67%
9.78% Other Institutional Investors
14.57% ETFs
35.67% Public Companies and
Individual Investors
The ownership structure of Denali Therapeutics (DNLI) stock is a mix of institutional, retail, and individual investors. Approximately 55.24% of the company’s stock is owned by Institutional Investors, 9.09% is owned by Insiders, and 35.67% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 22, 2024
Ryan J. Watts
President & Ceo,director
xxxxxxxxxxxxx
$53765
Aug 22, 2024
xxxxxxxxxxxxx
$41085
Aug 22, 2024
xxxxxxxxxxxxx
$58357
Aug 22, 2024
Alexander O. Schuth
Cofo And Secretary
xxxxxxxxxxxxx
$58357

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2024
xxxxxxxxxxxxx
$1313183
Jun 30, 2024
xxxxxxxxxxxxx
$11101667

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
10,491,377Institution7.29%328,904,669
9,620,007Institution6.68%301,587,219
8,797,384Institution6.11%275,797,988
6,301,778Institution4.38%197,560,740
5,750,882Insider4.20%180,290,151
5,275,368Institution3.67%165,382,787
3,905,970Institution2.71%122,452,160
3,731,695Institution2.59%116,988,638
2,438,411Insider1.69%76,444,185
2,117,408Insider1.47%66,380,741

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
9,620,007Institution6.68%301,587,219
8,797,384Institution6.11%275,797,988
5,275,368Institution3.67%165,382,787
3,905,970Institution2.71%122,452,160
1,543,042Institution1.07%48,374,367
1,385,920Institution0.96%43,448,592
1,374,416Institution0.95%43,087,942
1,141,086Institution0.79%35,773,046
1,101,938Institution0.77%34,545,756
1,053,092Institution0.73%33,014,434

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,383,589Institution2.35%106,075,515
3,329,465Institution2.31%96,987,315
2,686,518Institution1.87%78,258,269
1,857,418Institution1.29%54,106,586
1,481,816Institution1.03%43,165,300
1,326,945Institution0.92%39,277,572
837,567Institution0.58%26,257,725
642,916Institution0.45%20,155,417
594,326Institution0.41%17,592,050
570,202Institution0.40%16,609,984

FAQ

Who Owns Denali Therapeutics (DNLI)?
According to the latest TipRanks data, approximately 9.78% of the company's stock is held by institutional investors, 9.09% is held by insiders, and 35.67% is held by retail investors.
    What percentage of Denali Therapeutics (DNLI) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 9.78% of Denali Therapeutics (DNLI) stock is held by institutional investors.
      What percentage of Denali Therapeutics (DNLI) stock is held by retail investors?
      According to the latest TipRanks data, approximately 35.67% of Denali Therapeutics (DNLI) stock is held by retail investors.
        Who owns the most shares of Denali Therapeutics (DNLI)?
        Vanguard owns the most shares of Denali Therapeutics (DNLI).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis